Pluromed had been developing disposable medical devices based on reverse thermosensitive polymer technology. In March 2012, Pluromed Inc was acquired by French drug maker Sanofi. Pluromed, Inc. had beenpioneering the use of injectable plugs to improve the safety, efficacy and economics of medical interventions. The Company's family of disposable medical devices and its core competencies lay in its proprietary polymer technology, the manufacturing of these polymers, and a robust understanding of their clinical applications due in part to its outstanding medical advisory board. Pluromeds core strategy is targeted at the use of its devices to control bleeding during surgery. These products address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic reconstructive surgery and trauma/battlefield applications. A secondary strategy is the use of these devices in the treatment of kidney stones. The products are based on the Companys patented rapid reverse thermosensitive polymer technology. The polymers are liquid at low temperature and quickly transition to a high viscosity gel at body temperature
